A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G Jr, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ.
Reynolds KL, et al. Among authors: cohen e.
BMC Cancer. 2017 Sep 12;17(1):646. doi: 10.1186/s12885-017-3641-6.
BMC Cancer. 2017.
PMID: 28899363
Free PMC article.
Clinical Trial.